<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1924">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648582</url>
  </required_header>
  <id_info>
    <org_study_id>13439</org_study_id>
    <secondary_id>H9X-CR-GBDK</secondary_id>
    <nct_id>NCT01648582</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Mexico: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe
      compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who
      have inadequate glycemic control with 1 or 2 oral antihyperglycemic medications (OAM)
      (metformin and/or a sulfonylurea), in addition to any healthy lifestyle changes recommended
      by their healthcare providers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks</measure>
    <time_frame>Baseline, 26 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means of change from baseline in HbA1c were calculated using a mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, oral antihyperglycemic medication (OAM) , visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at 52 Weeks</measure>
    <time_frame>Baseline, 52 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means of change from baseline in HbA1c were calculated using a MMRM with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was as the random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Attaining HbA1c of &lt;7% or ≤6.5% at 26 Weeks and 52 Weeks</measure>
    <time_frame>Up to 26 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>LS means of change from baseline were calculated using MMRM with the change in FBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks and 52 Weeks</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were required to perform 7-point SMBG profiles on 2 separate, nonconsecutive days during the 2 weeks before randomization and Weeks 8, 14, 20, 26, 39, and 52 (or the Early Discontinuation Visit). SMBG measurements were taken using a plasma-equivalent blood glucose (BG) meter at 7 time points: morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. Mean and Week 26 and Week 52 was assessed in all treatment groups. LS means of change from baseline were calculated using MMRM with the change in 7-point SMBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks and 52 Weeks</measure>
    <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The updated Homeostasis Model Assessment (HOMA2) was used to quantify steady state beta-cell function (%B). HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate %B as a percentage of a normal reference population. LS means were calculated using an analysis of covariance (ANCOVA) model with change from baseline in HOMA-%B as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks and 52 Weeks</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The HOMA2 was used to estimate the steady-state insulin sensitivity (%S). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of the normal reference population. LS means were calculated using an ANCOVA model with change from baseline in HOMA-%S as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hypoglycemic Events</measure>
    <time_frame>Baseline through 26 weeks and 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hypoglycemic events (HE) were classified as documented symptomatic hypoglycemia, asymptomatic hypoglycemia, severe hypoglycemia, and probable symptomatic hypoglycemia. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Self-reported Hypoglycemic Events</measure>
    <time_frame>Baseline through 26 Weeks and 52 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia, and had a plasma glucose level of less than or equal to 3.9 millimoles/liter [mmol/L]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 Weeks and 52 Weeks on Blood Pressure (BP)</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 26 Weeks and 52 Weeks on Pulse Rate</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Seated pulse rate was measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiogram Parameters, Heart Rate (HR)</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Descriptive statistics for the actual measurements and LS means of change from baseline for HR (sitting) by treatment arm were analyzed using the analysis of variance (ANOVA) model with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline rate as a covariate, and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pancreatic Enzymes</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Amylase (total and pancreas-derived) and lipase concentrations were measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Calcitonin</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adjudicated Cardiovascular (CV) Events</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adjudicated Pancreatitis</measure>
    <time_frame>Baseline through 26 Weeks and 52 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Body mass index is an estimate of body fat based on body weight divided by height squared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Participants Developing Treatment-Emergent Dulaglutide Anti-drug Antibody (ADA)</measure>
    <time_frame>Baseline through 52 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant was considered to have TE dulaglutide ADA if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D Health State Score Responses</measure>
    <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life. It consists of 2 parts. The first part assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 3 response categories is summarized for each of the 5 dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D Visual Analog Scale Score</measure>
    <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score was self-reported using a visual analogue scale (VAS) marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. LS means of change from baseline were calculated using ANCOVA and adjusted by treatment, country, and baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">789</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Administered SC per dosing titration schedule</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.</description>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_label>Insulin Glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylureas</intervention_name>
    <description>Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.</description>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_label>Insulin Glargine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have type 2 diabetes mellitus for at least 6 months

          -  Have been taking metformin and/or a sulfonylurea for at least 3 months before
             screening and have been on a stable therapeutic dose for at least 8 weeks

          -  Glycosylated hemoglobin (HbA1c) value of ≥7.0% to ≤11.0%

          -  Adult men or adult non-pregnant, non-breastfeeding women

          -  Body Mass Index (BMI) of ≥19.0 to ≤35.0 kilograms/square meter (kg/m^2)

          -  Stable weight (±5%) ≥3 months prior to screening

        Exclusion Criteria:

          -  Have type 1 diabetes mellitus

          -  Have previous treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist,
             GLP-1 analog, or any other incretin mimetic

          -  Have treatment with dipeptidyl peptidase-IV (DPP-IV) inhibitor, an alpha-glucosidase
             inhibitor (AGI), thiazolidinedione (TZD), or glinide

          -  Have gastric emptying abnormality

          -  Have cardiac disorder defined as unstable angina, myocardial infarction, coronary
             artery bypass graft surgery, percutaneous coronary intervention, heart failure,
             arrhythmia, transient ischemic attack, or stroke

          -  Have poorly controlled hypertension (systolic blood pressure above 160 millimeter of
             mercury[mmHg] or diastolic blood pressure above 95 mmHg)

          -  Have impaired liver function

          -  Have impaired kidney function

          -  Have history of chronic pancreatitis or acute pancreatitis

          -  Have a serum calcitonin ≥20 picograms per milliliter (pg/mL)

          -  Have a personal or family history of medullary C-cell hyperplasia, focal hyperplasia,
             carcinoma, or multiple endocrine neoplasia type 2 (MEN 2)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changsha</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chongqing</city>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dalian</city>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guang Zhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guiyang</city>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hangzhou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Harbin</city>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanjing</city>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanning</city>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shenyang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wu Han</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Xi'An</city>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yangzhou</city>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zhenjiang</city>
        <zip>212000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucheon,</city>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyunggi-Do</city>
        <zip>425-020</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wonju-Si</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31238</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sankt-Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 21, 2015</lastchanged_date>
  <firstreceived_date>July 16, 2012</firstreceived_date>
  <firstreceived_results_date>May 8, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a parallel-arm, non-inferiority study. Study treatment continued for up to 52 weeks and participants were randomized in a 1:1:1 ratio to one of the 3 treatment arms: 1.5 milligrams (mg) dulaglutide once-weekly , 0.75 mg dulaglutide once-weekly, or insulin glargine once-daily.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1.5 mg Dulaglutide</title>
          <description>1.5 mg dulaglutide administered as 1 subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
        </group>
        <group group_id="P2">
          <title>0.75 mg Dulaglutide</title>
          <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
        </group>
        <group group_id="P3">
          <title>Insulin Glargine</title>
          <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant’s pre-study prescribed dose of metformin and /or a sulfonylurea.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="263"/>
                <participants group_id="P3" count="263"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="263"/>
                <participants group_id="P3" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent-to-Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="258"/>
                <participants group_id="P3" count="254"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="225"/>
                <participants group_id="P3" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are reported for the modified intent-to-treat (mITT) population, who are all randomized participants with a baseline glycosylated hemoglobin (HbA1c) measurement, at least 1 post-baseline HbA1c measurement, and received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>1.5 mg Dulaglutide</title>
          <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
        </group>
        <group group_id="B2">
          <title>0.75 mg Dulaglutide</title>
          <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
        </group>
        <group group_id="B3">
          <title>Insulin Glargine</title>
          <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="258"/>
                <measurement group_id="B2" value="258"/>
                <measurement group_id="B3" value="254"/>
                <measurement group_id="B4" value="770"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54.95" spread="9.742"/>
                <measurement group_id="B2" value="54.57" spread="9.924"/>
                <measurement group_id="B3" value="55.47" spread="9.215"/>
                <measurement group_id="B4" value="54.99" spread="9.629"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="123"/>
                <measurement group_id="B2" value="114"/>
                <measurement group_id="B3" value="113"/>
                <measurement group_id="B4" value="350"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="135"/>
                <measurement group_id="B2" value="144"/>
                <measurement group_id="B3" value="141"/>
                <measurement group_id="B4" value="420"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="13"/>
                <measurement group_id="B4" value="41"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="218"/>
                <measurement group_id="B2" value="215"/>
                <measurement group_id="B3" value="213"/>
                <measurement group_id="B4" value="646"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="28"/>
                <measurement group_id="B4" value="83"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Mexico</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="24"/>
                <measurement group_id="B4" value="70"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Russian Federation</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="54"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>China</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="205"/>
                <measurement group_id="B2" value="202"/>
                <measurement group_id="B3" value="199"/>
                <measurement group_id="B4" value="606"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="14"/>
                <measurement group_id="B4" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks</title>
        <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means of change from baseline in HbA1c were calculated using a mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, oral antihyperglycemic medication (OAM) , visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.</description>
        <time_frame>Baseline, 26 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who were randomized, received at least 1 dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant’s pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                  <measurement group_id="O2" value="258"/>
                  <measurement group_id="O3" value="254"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks</title>
            <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means of change from baseline in HbA1c were calculated using a mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, oral antihyperglycemic medication (OAM) , visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.</description>
            <units>percentage of HbA1c</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.70" spread="0.067"/>
                  <measurement group_id="O2" value="-1.32" spread="0.067"/>
                  <measurement group_id="O3" value="-1.15" spread="0.067"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Analyses were based on a pre-defined non-inferiority margin of 0.4%.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Analyses were based on a pre-defined non-inferiority margin of 0.4%.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>-0.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at 52 Weeks</title>
        <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means of change from baseline in HbA1c were calculated using a MMRM with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was as the random effect.</description>
        <time_frame>Baseline, 52 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who were randomized, received at least 1 dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant’s pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                  <measurement group_id="O2" value="258"/>
                  <measurement group_id="O3" value="254"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in HbA1c at 52 Weeks</title>
            <description>HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means of change from baseline in HbA1c were calculated using a MMRM with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was as the random effect.</description>
            <units>percentage of HbA1c</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.42" spread="0.076"/>
                  <measurement group_id="O2" value="-1.02" spread="0.076"/>
                  <measurement group_id="O3" value="-0.91" spread="0.077"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Analyses were based on a pre-defined non-inferiority margin of 0.4%.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Analyses were based on a pre-defined non-inferiority margin of 0.4%.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Attaining HbA1c of &lt;7% or ≤6.5% at 26 Weeks and 52 Weeks</title>
        <description>The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.</description>
        <time_frame>Up to 26 and 52 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who were randomized, received at least 1 dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline. Missing endpoints were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant’s pre-study prescribed dose of metformin and /or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                  <measurement group_id="O2" value="258"/>
                  <measurement group_id="O3" value="254"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Attaining HbA1c of &lt;7% or ≤6.5% at 26 Weeks and 52 Weeks</title>
            <description>The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HbA1c &lt;7%, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64.7"/>
                  <measurement group_id="O2" value="53.5"/>
                  <measurement group_id="O3" value="40.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HbA1c ≤6.5%, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50.8"/>
                  <measurement group_id="O2" value="39.1"/>
                  <measurement group_id="O3" value="21.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HbA1c &lt;7%, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51.6"/>
                  <measurement group_id="O2" value="45.7"/>
                  <measurement group_id="O3" value="32.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HbA1c ≤6.5%, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.8"/>
                  <measurement group_id="O2" value="31.0"/>
                  <measurement group_id="O3" value="16.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&lt;7.0% Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&lt;7.0 Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.004</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&lt;=6.5% Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&lt;=6.5% Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&lt;7.0% Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&lt;7.0% Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.002</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&lt;=6.5% Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&lt;=6.5% Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks</title>
        <description>LS means of change from baseline were calculated using MMRM with the change in FBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.</description>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who were randomized, received at least 1 dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant’s pre-study prescribed dose of metformin and /or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                  <measurement group_id="O2" value="258"/>
                  <measurement group_id="O3" value="254"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks</title>
            <description>LS means of change from baseline were calculated using MMRM with the change in FBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.</description>
            <units>millimoles per liter (mmol/L)</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Change from baseline in FBG, 26 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.27" spread="0.162"/>
                  <measurement group_id="O2" value="-1.71" spread="0.161"/>
                  <measurement group_id="O3" value="-2.57" spread="0.161"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from baseline in FBG, 52 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.17" spread="0.166"/>
                  <measurement group_id="O2" value="-1.53" spread="0.165"/>
                  <measurement group_id="O3" value="-2.36" spread="0.167"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.090</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.337</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks and 52 Weeks</title>
        <description>Participants were required to perform 7-point SMBG profiles on 2 separate, nonconsecutive days during the 2 weeks before randomization and Weeks 8, 14, 20, 26, 39, and 52 (or the Early Discontinuation Visit). SMBG measurements were taken using a plasma-equivalent blood glucose (BG) meter at 7 time points: morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. Mean and Week 26 and Week 52 was assessed in all treatment groups. LS means of change from baseline were calculated using MMRM with the change in 7-point SMBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.</description>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who were randomized, received at least 1 dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant’s pre-study prescribed dose of metformin and /or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                  <measurement group_id="O2" value="258"/>
                  <measurement group_id="O3" value="254"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks and 52 Weeks</title>
            <description>Participants were required to perform 7-point SMBG profiles on 2 separate, nonconsecutive days during the 2 weeks before randomization and Weeks 8, 14, 20, 26, 39, and 52 (or the Early Discontinuation Visit). SMBG measurements were taken using a plasma-equivalent blood glucose (BG) meter at 7 time points: morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. Mean and Week 26 and Week 52 was assessed in all treatment groups. LS means of change from baseline were calculated using MMRM with the change in 7-point SMBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.</description>
            <units>mmol/L</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Morning pre-meal, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.13" spread="0.105"/>
                  <measurement group_id="O2" value="-1.85" spread="0.103"/>
                  <measurement group_id="O3" value="-2.80" spread="0.103"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Morning 2 hours post-meal, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.79" spread="0.190"/>
                  <measurement group_id="O2" value="-3.41" spread="0.187"/>
                  <measurement group_id="O3" value="-3.26" spread="0.187"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mid-day pre-meal, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.42" spread="0.162"/>
                  <measurement group_id="O2" value="-2.00" spread="0.159"/>
                  <measurement group_id="O3" value="-2.09" spread="0.159"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mid-day 2 hours post-meal, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.14" spread="0.182"/>
                  <measurement group_id="O2" value="-2.64" spread="0.178"/>
                  <measurement group_id="O3" value="-2.09" spread="0.178"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Evening pre-meal, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.23" spread="0.151"/>
                  <measurement group_id="O2" value="-1.69" spread="0.147"/>
                  <measurement group_id="O3" value="-1.59" spread="0.147"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Evening 2 hours post-meal, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.96" spread="0.180"/>
                  <measurement group_id="O2" value="-2.46" spread="0.177"/>
                  <measurement group_id="O3" value="-2.11" spread="0.177"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bed time, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.89" spread="0.171"/>
                  <measurement group_id="O2" value="-2.42" spread="0.169"/>
                  <measurement group_id="O3" value="-2.16" spread="0.167"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Morning pre-meal, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.02" spread="0.108"/>
                  <measurement group_id="O2" value="-1.76" spread="0.107"/>
                  <measurement group_id="O3" value="-2.81" spread="0.106"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Morning 2 hours post-meal, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.59" spread="0.199"/>
                  <measurement group_id="O2" value="-3.28" spread="0.198"/>
                  <measurement group_id="O3" value="-3.04" spread="0.195"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mid-day pre-meal, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.34" spread="0.163"/>
                  <measurement group_id="O2" value="-1.91" spread="0.161"/>
                  <measurement group_id="O3" value="-1.97" spread="0.159"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mid-day 2 hours post-meal, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.76" spread="0.186"/>
                  <measurement group_id="O2" value="-2.62" spread="0.184"/>
                  <measurement group_id="O3" value="-2.15" spread="0.182"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Evening pre-meal, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.08" spread="0.159"/>
                  <measurement group_id="O2" value="-1.58" spread="0.157"/>
                  <measurement group_id="O3" value="-1.48" spread="0.155"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Evening 2 hours post-meal, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.89" spread="0.184"/>
                  <measurement group_id="O2" value="-2.47" spread="0.182"/>
                  <measurement group_id="O3" value="-2.09" spread="0.180"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bed time, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.89" spread="0.171"/>
                  <measurement group_id="O2" value="-2.48" spread="0.170"/>
                  <measurement group_id="O3" value="-1.91" spread="0.167"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning pre-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning pre-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning 2-hours post-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.014</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning 2-hours post-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.464</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mid-day pre-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.069</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mid-day pre-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.661</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mid-day 2-hours post-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>-0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mid-day 2-hours post-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.007</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening pre-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening pre-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.584</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening 2-hours post-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>-0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening 2-hours post-meal, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.081</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bedtime, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bedtime, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.182</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning pre-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning pre-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning 2-hours post-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.018</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning 2-hours post-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.301</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mid-day pre-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.049</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>-0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mid-day pre-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.755</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mid-day 2-hours post-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mid-day 2-hours post-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.029</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening pre-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening pre-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.604</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening 2-hours post-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening 2-hours post-meal, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.076</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bedtime, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.37</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bedtime, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks and 52 Weeks</title>
        <description>The updated Homeostasis Model Assessment (HOMA2) was used to quantify steady state beta-cell function (%B). HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate %B as a percentage of a normal reference population. LS means were calculated using an analysis of covariance (ANCOVA) model with change from baseline in HOMA-%B as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.</description>
        <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who were randomized, received at least 1 dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline. Missing endpoints were imputed with the LOCF method. HOMA2 was not evaluated for insulin glargine, as the use of this model has not been validated in participants treated with insulin.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                  <measurement group_id="O2" value="258"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks and 52 Weeks</title>
            <description>The updated Homeostasis Model Assessment (HOMA2) was used to quantify steady state beta-cell function (%B). HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate %B as a percentage of a normal reference population. LS means were calculated using an analysis of covariance (ANCOVA) model with change from baseline in HOMA-%B as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.</description>
            <units>percentage of HOMA2-%B</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Change from baseline in HOMA2-%B, 26 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.40" spread="3.854"/>
                  <measurement group_id="O2" value="31.77" spread="3.783"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from baseline in HOMA2-%B, 52 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44.52" spread="4.119"/>
                  <measurement group_id="O2" value="36.67" spread="4.024"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HOMA2-%B, Dula 0.75 mg, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.631</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>44.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.849</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HOMA2-%B, Dula 1.5 mg, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.631</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>31.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.770</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HOMA2-%B, Dula 0.75, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.036</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>44.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.119</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HOMA2-%B, Dula 1.5 mg, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.036</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>36.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.024</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks and 52 Weeks</title>
        <description>The HOMA2 was used to estimate the steady-state insulin sensitivity (%S). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of the normal reference population. LS means were calculated using an ANCOVA model with change from baseline in HOMA-%S as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.</description>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who were randomized, received at least 1 dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline. Missing endpoints were imputed with the LOCF method. HOMA2 was not evaluated for insulin glargine, as the use of this model has not been validated in participants treated with insulin.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                  <measurement group_id="O2" value="258"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks and 52 Weeks</title>
            <description>The HOMA2 was used to estimate the steady-state insulin sensitivity (%S). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of the normal reference population. LS means were calculated using an ANCOVA model with change from baseline in HOMA-%S as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.</description>
            <units>percentage of HOMA2-%S</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Change from baseline in HOMA2-%S, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-7.19" spread="3.623"/>
                  <measurement group_id="O2" value="-9.72" spread="3.555"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from baseline in HOMA2-%S, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.79" spread="3.707"/>
                  <measurement group_id="O2" value="-11.52" spread="3.627"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HOMA2-%S, Dula 0.75, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.441</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.623</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HOMA2-%S, Dula 1.5 mg, Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.441</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-9.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.555</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HOMA2-%S, Dula 0.75 mg, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.607</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-9.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.707</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HOMA2-%S, Dula 1.5 mg, Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.607</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-11.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.627</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Hypoglycemic Events</title>
        <description>Hypoglycemic events (HE) were classified as documented symptomatic hypoglycemia, asymptomatic hypoglycemia, severe hypoglycemia, and probable symptomatic hypoglycemia. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 26 weeks and 52 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant’s pre-study prescribed dose of metformin and /or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Rate of Hypoglycemic Events</title>
            <description>Hypoglycemic events (HE) were classified as documented symptomatic hypoglycemia, asymptomatic hypoglycemia, severe hypoglycemia, and probable symptomatic hypoglycemia. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
            <units>events per participant per year</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>1-year Rate of HE, Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.18" spread="4.371"/>
                  <measurement group_id="O2" value="0.96" spread="4.103"/>
                  <measurement group_id="O3" value="1.96" spread="6.278"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe HE Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.00" spread="0.000"/>
                  <measurement group_id="O2" value="0.00" spread="0.000"/>
                  <measurement group_id="O3" value="0.00" spread="0.000"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nocturnal HE Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.17" spread="0.865"/>
                  <measurement group_id="O2" value="0.15" spread="0.800"/>
                  <measurement group_id="O3" value="0.36" spread="1.250"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1-year Rate of HE, Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.84" spread="3.721"/>
                  <measurement group_id="O2" value="0.76" spread="3.811"/>
                  <measurement group_id="O3" value="1.76" spread="6.544"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe HE Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.00" spread="0.000"/>
                  <measurement group_id="O2" value="0.00" spread="0.000"/>
                  <measurement group_id="O3" value="0.00" spread="0.000"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nocturnal HE Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.10" spread="0.469"/>
                  <measurement group_id="O2" value="0.11" spread="0.569"/>
                  <measurement group_id="O3" value="0.26" spread="0.979"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Self-reported Hypoglycemic Events</title>
        <description>Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia, and had a plasma glucose level of less than or equal to 3.9 millimoles/liter [mmol/L]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 26 Weeks and 52 Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Self-reported Hypoglycemic Events</title>
            <description>Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia, and had a plasma glucose level of less than or equal to 3.9 millimoles/liter [mmol/L]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Total HE Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.3"/>
                  <measurement group_id="O2" value="17.5"/>
                  <measurement group_id="O3" value="28.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe HE Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="0.0"/>
                  <measurement group_id="O3" value="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nocturnal HE Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.7"/>
                  <measurement group_id="O2" value="4.6"/>
                  <measurement group_id="O3" value="11.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Documented Symptomatic Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.6"/>
                  <measurement group_id="O2" value="8.0"/>
                  <measurement group_id="O3" value="17.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Asymptomatic HE Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.3"/>
                  <measurement group_id="O2" value="8.4"/>
                  <measurement group_id="O3" value="13.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Probable HE Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4"/>
                  <measurement group_id="O2" value="4.9"/>
                  <measurement group_id="O3" value="6.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total HE Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.3"/>
                  <measurement group_id="O2" value="20.5"/>
                  <measurement group_id="O3" value="33.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe HE Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="0.0"/>
                  <measurement group_id="O3" value="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nocturnal HE Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.5"/>
                  <measurement group_id="O2" value="4.9"/>
                  <measurement group_id="O3" value="13.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Documented Symptomatic HE Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.8"/>
                  <measurement group_id="O2" value="9.9"/>
                  <measurement group_id="O3" value="20.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Asymptomatic HE Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.2"/>
                  <measurement group_id="O2" value="10.3"/>
                  <measurement group_id="O3" value="18.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Probable HE Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.8"/>
                  <measurement group_id="O2" value="5.3"/>
                  <measurement group_id="O3" value="7.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 Weeks and 52 Weeks on Blood Pressure (BP)</title>
        <description>Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant’s pre-study prescribed dose of metformin and /or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to 26 Weeks and 52 Weeks on Blood Pressure (BP)</title>
            <description>Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
            <units>millimeters of mercury (mmHg)]</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>SBP 26 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.60" spread="11.925"/>
                  <measurement group_id="O2" value="-2.94" spread="11.918"/>
                  <measurement group_id="O3" value="-2.02" spread="12.806"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DBP 26 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.67" spread="7.836"/>
                  <measurement group_id="O2" value="-1.03" spread="7.888"/>
                  <measurement group_id="O3" value="-1.51" spread="8.396"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SBP 52 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.99" spread="10.953"/>
                  <measurement group_id="O2" value="-0.64" spread="12.080"/>
                  <measurement group_id="O3" value="-0.15" spread="11.728"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DBP 52 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.0" spread="7.473"/>
                  <measurement group_id="O2" value="0.39" spread="7.557"/>
                  <measurement group_id="O3" value="-1.13" spread="8.756"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26 SBP</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26 DBP</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.671</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 SBP</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.206</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 DBP</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.110</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 26 Weeks and 52 Weeks on Pulse Rate</title>
        <description>Seated pulse rate was measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline at 26 Weeks and 52 Weeks on Pulse Rate</title>
            <description>Seated pulse rate was measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
            <units>beats per minute (bpm)</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Change From Baseline on Pulse rate at Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.71" spread="8.626"/>
                  <measurement group_id="O2" value="3.34" spread="8.600"/>
                  <measurement group_id="O3" value="-0.07" spread="8.787"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change From Baseline on Pulse rate at Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.24" spread="8.356"/>
                  <measurement group_id="O2" value="3.23" spread="8.872"/>
                  <measurement group_id="O3" value="0.05" spread="8.223"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval</title>
        <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant’s pre-study prescribed dose of metformin and /or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval</title>
            <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
            <units>millisecond (msec)</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>QTcF Interval 26 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.41" spread="13.357"/>
                  <measurement group_id="O2" value="0.80" spread="11.571"/>
                  <measurement group_id="O3" value="2.69" spread="11.966"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PR Interval 26 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.70" spread="12.095"/>
                  <measurement group_id="O2" value="3.11" spread="10.797"/>
                  <measurement group_id="O3" value="-0.88" spread="10.253"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>QTcF Interval 52 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.83" spread="11.451"/>
                  <measurement group_id="O2" value="1.33" spread="12.075"/>
                  <measurement group_id="O3" value="3.93" spread="11.431"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PR Interval 52 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.50" spread="12.389"/>
                  <measurement group_id="O2" value="3.61" spread="11.578"/>
                  <measurement group_id="O3" value="0.68" spread="11.777"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Electrocardiogram Parameters, Heart Rate (HR)</title>
        <description>Descriptive statistics for the actual measurements and LS means of change from baseline for HR (sitting) by treatment arm were analyzed using the analysis of variance (ANOVA) model with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline rate as a covariate, and participant as a random effect.</description>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Electrocardiogram Parameters, Heart Rate (HR)</title>
            <description>Descriptive statistics for the actual measurements and LS means of change from baseline for HR (sitting) by treatment arm were analyzed using the analysis of variance (ANOVA) model with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline rate as a covariate, and participant as a random effect.</description>
            <units>beats per minute (bpm)</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.15" spread="8.885"/>
                  <measurement group_id="O2" value="3.77" spread="8.952"/>
                  <measurement group_id="O3" value="-0.54" spread="9.283"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.15" spread="8.230"/>
                  <measurement group_id="O2" value="3.50" spread="7.987"/>
                  <measurement group_id="O3" value="0.48" spread="8.003"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pancreatic Enzymes</title>
        <description>Amylase (total and pancreas-derived) and lipase concentrations were measured</description>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Pancreatic Enzymes</title>
            <description>Amylase (total and pancreas-derived) and lipase concentrations were measured</description>
            <units>Units/Liter (U/L)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Amylase, Total 26 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.37" spread="18.645"/>
                  <measurement group_id="O2" value="7.40" spread="22.281"/>
                  <measurement group_id="O3" value="-0.34" spread="18.051"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Amylase, pancreas derived 26 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.79" spread="14.491"/>
                  <measurement group_id="O2" value="5.05" spread="19.213"/>
                  <measurement group_id="O3" value="-0.20" spread="11.193"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lipase 26 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.85" spread="33.866"/>
                  <measurement group_id="O2" value="10.45" spread="39.708"/>
                  <measurement group_id="O3" value="-2.81" spread="21.656"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Amylase, Total 52 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.68" spread="16.236"/>
                  <measurement group_id="O2" value="6.22" spread="20.560"/>
                  <measurement group_id="O3" value="0.66" spread="18.545"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Amylase, pancreas derived 52 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.41" spread="12.396"/>
                  <measurement group_id="O2" value="3.99" spread="15.304"/>
                  <measurement group_id="O3" value="-0.46" spread="12.655"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lipase 52 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.50" spread="27.296"/>
                  <measurement group_id="O2" value="9.66" spread="33.339"/>
                  <measurement group_id="O3" value="-3.74" spread="20.329"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Calcitonin</title>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Serum Calcitonin</title>
            <units>picomole/liter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.01" spread="0.239"/>
                  <measurement group_id="O2" value="-0.07" spread="0.289"/>
                  <measurement group_id="O3" value="0.02" spread="0.254"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.95" spread="14.203"/>
                  <measurement group_id="O2" value="0.31" spread="37.297"/>
                  <measurement group_id="O3" value="-2.45" spread="14.290"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adjudicated Cardiovascular (CV) Events</title>
        <description>Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Adjudicated Cardiovascular (CV) Events</title>
            <description>Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
            <units>participants with adjudicated CV events</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adjudicated Pancreatitis</title>
        <description>Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 26 Weeks and 52 Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Adjudicated Pancreatitis</title>
            <description>Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>26 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>52 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight</title>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Body Weight</title>
            <units>kilogram (kg)</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.51" spread="0.197"/>
                  <measurement group_id="O2" value="-0.87" spread="0.196"/>
                  <measurement group_id="O3" value="0.96" spread="0.197"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.14" spread="0.202"/>
                  <measurement group_id="O2" value="-0.78" spread="0.202"/>
                  <measurement group_id="O3" value="1.34" spread="0.201"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Week 26</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index</title>
        <description>Body mass index is an estimate of body fat based on body weight divided by height squared.</description>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Body Mass Index</title>
            <description>Body mass index is an estimate of body fat based on body weight divided by height squared.</description>
            <units>kilogram/square meter (kg/m2)</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.55" spread="0.071"/>
                  <measurement group_id="O2" value="-0.32" spread="0.071"/>
                  <measurement group_id="O3" value="0.36" spread="0.071"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.41" spread="0.073"/>
                  <measurement group_id="O2" value="-0.27" spread="0.073"/>
                  <measurement group_id="O3" value="0.52" spread="0.072"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Participants Developing Treatment-Emergent Dulaglutide Anti-drug Antibody (ADA)</title>
        <description>Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant was considered to have TE dulaglutide ADA if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.</description>
        <time_frame>Baseline through 52 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the safety population who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="263"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Participants Developing Treatment-Emergent Dulaglutide Anti-drug Antibody (ADA)</title>
            <description>Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant was considered to have TE dulaglutide ADA if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Participants with &gt;=1 TE Dula ADA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.8"/>
                  <measurement group_id="O2" value="4.2"/>
                  <measurement group_id="O3" value="1.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Participants with TE Dula ADA and Neutralizing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.8"/>
                  <measurement group_id="O2" value="1.5"/>
                  <measurement group_id="O3" value="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EQ-5D Health State Score Responses</title>
        <description>The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life. It consists of 2 parts. The first part assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 3 response categories is summarized for each of the 5 dimensions.</description>
        <time_frame>Baseline, 26 Weeks, 52 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who were randomized, received at least 1 dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                  <measurement group_id="O2" value="258"/>
                  <measurement group_id="O3" value="254"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>EQ-5D Health State Score Responses</title>
            <description>The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life. It consists of 2 parts. The first part assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 3 response categories is summarized for each of the 5 dimensions.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Mobility - no problem Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="223"/>
                  <measurement group_id="O3" value="215"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mobility - some problem Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mobility - extreme problem Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mobility - missing Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Self-care - no problem Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="230"/>
                  <measurement group_id="O2" value="234"/>
                  <measurement group_id="O3" value="230"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Self-care - some problem Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Self-care - extreme problem Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Self-care - missing Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Usual activities - no problems Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="227"/>
                  <measurement group_id="O2" value="227"/>
                  <measurement group_id="O3" value="224"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Usual activities - some problems Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Usual activities - extreme problems Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Usual activities - missing Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain/Discomfort - no problems Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="202"/>
                  <measurement group_id="O2" value="211"/>
                  <measurement group_id="O3" value="213"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain/Discomfort - some problems Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="27"/>
                  <measurement group_id="O3" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain/Discomfort - extreme problems Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain/Discomfort - missing Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety/Depression - no problems Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="215"/>
                  <measurement group_id="O2" value="211"/>
                  <measurement group_id="O3" value="213"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety/Depression - some problems Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="27"/>
                  <measurement group_id="O3" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety/Depression - extreme problems Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety/Depression - missing Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mobility - no problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="216"/>
                  <measurement group_id="O3" value="218"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mobility - some problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mobility - extreme problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mobility - missing Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Self-care - no problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="224"/>
                  <measurement group_id="O3" value="227"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Self-care - some problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Self-care - extreme problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Self-care - missing Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Usual Activities - no problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="220"/>
                  <measurement group_id="O3" value="223"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Usual Activities - some problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Usual Activities - extreme problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Usual Activities - missing Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain/Discomfort - no problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                  <measurement group_id="O2" value="197"/>
                  <measurement group_id="O3" value="192"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain/Discomfort - some problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain/Discomfort - extreme problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain/Discomfort - missing Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety/Depression - no problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="214"/>
                  <measurement group_id="O2" value="215"/>
                  <measurement group_id="O3" value="207"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety/Depression - some problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety/Depression - extreme problems Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety/Depression - missing Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D Visual Analog Scale Score</title>
        <description>The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score was self-reported using a visual analogue scale (VAS) marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. LS means of change from baseline were calculated using ANCOVA and adjusted by treatment, country, and baseline.</description>
        <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who were randomized, received at least 1 dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Dulaglutide</title>
            <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg Dulaglutide</title>
            <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                  <measurement group_id="O2" value="258"/>
                  <measurement group_id="O3" value="254"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in EQ-5D Visual Analog Scale Score</title>
            <description>The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score was self-reported using a visual analogue scale (VAS) marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. LS means of change from baseline were calculated using ANCOVA and adjusted by treatment, country, and baseline.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 26</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.55" spread="13.249"/>
                  <measurement group_id="O2" value="1.32" spread="12.004"/>
                  <measurement group_id="O3" value="2.13" spread="15.876"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 52</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.32" spread="13.731"/>
                  <measurement group_id="O2" value="2.06" spread="12.769"/>
                  <measurement group_id="O3" value="3.69" spread="16.421"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1.5 mg Dulaglutide</title>
          <description>1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
        </group>
        <group group_id="E2">
          <title>0.75 mg Dulaglutide</title>
          <description>0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.</description>
        </group>
        <group group_id="E3">
          <title>Insulin Glargine</title>
          <description>Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant’s pre-study prescribed dose of metformin and /or a sulfonylurea.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cerebrovascular stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Perinephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Microcytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="87" subjects_affected="41" subjects_at_risk="263"/>
                <counts group_id="E2" events="48" subjects_affected="25" subjects_at_risk="263"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="263"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="19" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Non-alcoholic steatohepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Post cholecystectomy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cat scratch disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="263"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E3" events="26" subjects_affected="19" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="263"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Exposure via father</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Albumin urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E2" events="14" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood potassium abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood triglycerides</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Carbohydrate antigen 19-9 increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Crystal urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Electrocardiogram t wave abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>High density lipoprotein decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="263"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Protein urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Urine albumin/creatinine ratio increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hyperamylasaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="263"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="263"/>
                <counts group_id="E3" events="30" subjects_affected="29" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Marrow hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cerebral artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Diabetic autonomic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Viith nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hypertensive nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Nephroptosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Choking sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Urticaria contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Lung lobectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Modified radical mastectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
